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Abstract
Chemotherapy has been reported to upregulate sphingomylinases and increase cel-
lular ceramide, often linked to the induction to cell death. In this work, we show 
that sublethal doses of doxorubicin and vorinostat still increased cellular ceramide, 
which was located predominantly at the plasma membrane. To interrogate possi-
ble functions of this specific pool of ceramide, we used recombinant enzymes to 
mimic physiological levels of ceramide at the plasma membrane upon chemotherapy 
treatment. Using mass spectrometry and network analysis, followed by experimental 
confirmation, the results revealed that this pool of ceramide acutely regulates cell 
adhesion and cell migration pathways with weak connections to commonly estab-
lished ceramide functions (eg, cell death). Neutral sphingomyelinase 2 (nSMase2) 
was identified as responsible for the generation of plasma membrane ceramide upon 
chemotherapy treatment, and both ceramide at the plasma membrane and nSMase2 
were necessary and sufficient to mediate these “side” effects of chemotherapy on 
cell adhesion and migration. This is the first time a specific pool of ceramide is 
interrogated for acute signaling functions, and the results define plasma membrane 
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1 |  INTRODUCTION
Studies spanning three decades have shown the bioactive 
sphingolipid ceramide to be involved in a myriad of biol-
ogies, the most prominent of which are the induction of 
growth arrest and cell death.1 However, ceramide species 
have been found to also mediate/regulate cytokine secre-
tion, vesicle transport, and cell cycle. Ceramide is also 
involved in mechanisms employed by some pathogenic 
bacteria and viruses in order to engage and penetrate mam-
malian cells.2 The molecular mechanisms on how ceramide 
mediates these biologies are still not fully determined, al-
though a few direct targets have been advanced, including 
atypical PKC, cathepsin D, protein phosphatases 1 and 
2A, and VDAC.3,4 Moreover, the specific subcellular (ie, 
organelle) location for ceramide function is still not fully 
understood. Birbes et al reported that targeting bacterial 
sphingomyelinase (bSMase) to mitochondria—but not to 
other compartments—in the cell-induced apoptosis,5 and 
this finding has been supported and extended by more 
recent experimental studies on regulating mitochondrial 
ceramide by specifically transferring it from the ER to mi-
tochondria.6 Moreover, in earlier studies, our group and 
other investigators had found that generating plasma mem-
brane ceramide through exogenously applied sphingomy-
elinases (SMases) did not induce cell death in many cell 
lines although it induced hemolysis in erythrocytes.7,8
These studies and several other lines of evidence prompted 
the development of the “Many Ceramides” hypothesis,9 
which posits that different species of ceramide(s) at differ-
ent cellular membranes are involved in different biological 
phenomena. These compartment-specific pathways would 
presumably operate in response to distinct stimuli that pu-
tatively activate specific enzymes of ceramide generation. 
Surprisingly, barely any of the previous studies hypothe-
sized where ceramide at the onset of a specific cell biologic 
response is generated and localized. On a further level of 
complexity, ceramide can also be metabolized to other lip-
ids, and these byproducts may potentially be responsible for 
the observed cell signaling and cellular responses.10 For ex-
ample, actions of tumor necrosis factor (TNF) on SMases in 
fibroblasts results in subsequent formation of sphingosine 
1-phosphate (S1P), which in turn promotes cell prolifera-
tion.11 In this context, it is becoming increasingly clear that 
ceramide-mediated cellular responses have to be investigated 
at the level of specific enzymes and specific subcellular com-
partments, while also taking into consideration the likelihood 
of further metabolism.
One of the challenges in dissecting and/or studying ce-
ramide signaling is the lack of biochemical pathways that 
are promptly activated to induce the ceramide generation. 
Indeed, the vast majority of studies on ceramide signaling use 
either exogenously applied ceramides12,13 or ceramide induc-
ers, and responses often occur many hours or even days after 
induction.14 The localization of this generated or applied ce-
ramide and their associated metabolism are not well defined. 
Moreover, many of the inducers used to generate endogenous 
ceramide may regulate more than a single pathway of cera-
mide generation15; thus, greatly complicating the dissection 
of specific ceramide-mediated cell signaling pathways.
To address such challenges, a few analytical approaches 
have been used in order to identify direct targets that might 
propagate the subsequent steps in signaling after initial cer-
amide generation. The most direct biochemical approaches 
have utilized mostly short chain ceramide species bound to 
agarose beads for either affinity chromatography columns or 
in tandem pull-down/mass spectrometry studies.16 Other as-
says use functionalized ceramides that may be cross-linked 
with docking proteins to functionalized beads.17,18 Together, 
these classic studies have found many associated proteins 
that bind ceramide and may be activated or inhibited, but still 
lacking the context on cellular topology.
In our own research group, we have long studied protein 
phosphatases that not only have been found to bind ceramide, 
but that are also directly activated in vitro by natural ceramide 
but not unnatural stereoisomers, thereby showing stereospec-
ificity for the natural ceramide.19,20 Indeed, in previous work, 
we have found that the PP1 family of phosphatases can be ac-
tivated in cellulo by ceramide within just a few minutes after 
its generation in situ.21 Although the site of action was not de-
fined, this might be the most robust effector for ceramide so 
far reported, and in this work, we used changes in protein (de)
phosphorylation to screen for most direct ceramide actions.
Here, in order to advance studies on compartment-specific 
functions, we have focused on plasma membrane ceramide to 
determine if there are specific biological attributes to that sub-
cellular pool. Toward this goal, we screened for compounds that 
could potentially generate ceramide in the plasma membrane. 
ceramide as an acute signaling effector necessary and sufficient for regulation of cell 
adhesion and cell migration under chemotherapeutical stress.
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We found doxorubicin and vorinostat generated ceramide at 
the plasma membrane, even at sublethal doses. Using recom-
binant tools, we acutely generated ceramide at the plasma 
membrane and defined the experimental conditions in which 
this particular pool of ceramide remained in the plasma mem-
brane. Under these conditions, we screened which proteins un-
derwent changes in the corresponding phosphorylation status. 
The results showed that plasma membrane-generated ceramide 
induces acute dephosphorylation of a large set of substrates reg-
ulating cell adhesion and migration. Interestingly, it has been re-
ported that some chemotherapeutic treatments, including those 
from doxorubicin and vorinostat, present side effects including 
modulation of cell adhesion resulting in increasing the risk in 
cell invasion and metastasis,22 suggesting that these biologies 
are mediated by plasma membrane ceramide under the control 
of chemotherapy.
In summary, this work defines three novel key points 
about the mechanism on how sublethal doses of chemother-
apy lead to increase cancer cell migration. First, chemother-
apy increases expression of nSMase2. Elevation of nSMase2 
is sufficient to drive cell migration, and suppression or inhi-
bition of nSMase2 shows it is necessary for the chemotherapy 
effects on migration. Second, nSMase2 acts on the plasma 
membrane, generating a previously uncharacterized pool of 
ceramide, which our data show to mediate the effects on cell 
migration. Third, the mechanism on how ceramide acts on 
a biological pathway by acutely inducing protein (de)phos-
phorylation, leading to regulation of adhesion and migration.
2 |  MATERIALS AND METHODS
2.1 | Cell culture
All cell culture media (DMEM, OPTI-MEM, and FBS), 
DPBS, Human Fibronectin MW 440KDa and BCA Protein 
Assay Kit (cat# 23225) were purchased from Thermo Fisher 
(Waltham, MS, USA). Fluorescent-conjugated antibodies 
were from Invitrogen (Waltham, MS, USA) (donkey/Goat 
anti-mouse/rabbit Alexa Fluor 488/555). Xtremegene 9 DNA 
Transfection reagent, fatty acid-free bovine serum albumin 
(BSA) lyophilized powder (cat#126609), Optiprep density 
gradient medium Doxorubicin and vorinostat were pur-
chased from Sigma (St. Louis, MO, USA). The nuclear stain-
ing using DAPI with mounting medium (H-1200) was from 
Vector Laboratories (Burlingame, CA, USA). The mouse 
hybridoma clone 2A2 was generated and its cognate anti-
ceramide IgM monoclonal antibodies purified as previously 
reported.23 HeLa human cervical carcinoma cells (ATCC, 
Manassas, VA, USA), were maintained in DMEM supple-
mented with 10% FBS. Cells were incubated and imaged in 
a humidified environment at 37°C with 5% CO2. Cells were 
monthly evaluated for mycoplasma and annually typed.
2.2 | Cell viability assay
Cell viability was measured using the oxidation of the water 
soluble 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) to the insoluble formazan (Sigma, 
St. Louis, MO, USA), quantified by absorbance at 570 nm 
(SpectraMax M5, Molecular Devices). HeLa cells were 
seeded in 6-well plate at 10^5 cells/ml/well. At the end of 
the treatment period, medium was removed and replaced 
with fresh medium. MTT (5 mg/mL) in fresh DMEM me-
dium was added to each well at 37°C for 2 hours. Formazan 
product was solubilized in DMSO and absorbance was 
measured.
2.3 | Lactate dehydrogenase release assay
Lactate dehydrogenase (LDH) release was determined using 
a colorimetric assay kit (Biovision, Milpitas, CA) following 
the manufacturer's instructions.
2.4 | Protein expression and purification
His-Venus-Lysenin,24 bSMase from Bacillus cereus,7 
and Pseudomonas bacterial ceramidase (pCDase) from 
Pseudomonas aeruginosa25 were expressed in Escherichia 
coli BL21 DE3 and purified as previously described with 
minor modifications.7 Briefly, four liters of Terrific Broth 
was inoculated with bacteria, and bacteria were induced with 
1 mM of isopropyl β-D-1 thiogalactopyranoside (IPTG), fol-
lowed by incubation at 25ºC for 16 hours. Pelleted bacteria 
were kept at −80ºC until purification. Pellets were thawed 
and sonicated with on/off cycles at 85% of amplitude (58W) 
during a 5-minute series (2s on/2s off); sonication was pro-
longed until the bacteria were visually cleared. Lysate was 
centrifuged and filtered through a 0.22 µm filter. Purification 
of His-tagged proteins was performed using a HisTrap FF 
column (GE Healthcare Life Sciences, Chicago, IL, USA) 
followed by size-exclusion chromatography (Superdex 200) 
in an ÄKTA purifier system. Fractions containing pure pro-
teins were combined, the final volume was concentrated to 
1  mg/mL, frozen directly in liquid nitrogen, and stored at 
−80ºC until use.
2.5 | Reverse-transcriptase PCR
mRNA from HeLa cells was extracted using the RNeasy kit 
(Qiagen, Venlo, Netherlands). RNA (0.5-1 μg) was used to 
synthesize cDNA with the Superscript III Kit (Invitrogen). 
Real-time PCR was performed using the Taqman assays on 
an ABI 7500 real-time system. Standard reaction volume 
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was 20 µL containing 10 µL of supermix, 4.67 µL of dH2O, 
0.33 µL of 60 × Taqman assay, and 5 µL of cDNA tem-
plate. The quantitative PCR protocol consisted of 2 min-
utes at 50°C followed by 10 minutes at 95°C, and 40 cycles 
consisting of a 15 seconds at 95°C and 60 seconds at 60°C. 
All reactions were in triplicates. Actin was used as a ref-
erence gene in all cases, and Ct values were converted 
to mean normalized expression using the ΔΔCt method. 
Taqman assays were purchased from Life Technologies 
(gene: Taqman assay number. actin: Hs99999903_m1, 
neutral SMase 2: Hs00920354_m1).
2.6 | siRNA and plasmid DNA transfection
Cells were maintained at 37°C, 5% CO2 in a humidified 
atmosphere. For siRNA experiments, 300 000 HeLa cells 
were cultured in 100 mm dishes with media being changed 
1  hour before transfection. Cells were transfected with 
20  nM negative control (AllStar, Qiagen) or siRNA for 
nSMAse2 (gene symbol SMPD3, siRNAs Life technolo-
gies s30926, and results confirmed using s30927) using 
lipofectamine RNAimax (Life Technologies, Chicago, 
IL, USA) according to the manufacturer's protocol. After 
48 hours, cells were incubated in fresh media for 1-2 hours 
prior to stimulation as indicated. For overexpression exper-
iments, HeLa cells were transfected at confluence in 60 mm 
dishes (500K cells/dish) with V5-nSMase2 (SMPD3) pre-
viously described26 and using Xtremegene 9 standard pro-
tocol (SIGMA).
2.7 | Wound healing (scratch) assays
Cell wound healing (scratch) assay was adapted from Liang 
et al27 Briefly, 12-well plate were coated with fibronectin-1 
(FN1) 5 µg/mL for 16 hours (overnight). Wells were washed 
with PBS three times. Cells were plated at 200K cells/well 
to generate a confluent monolayer of cells and was left over-
night to attach. The appropriate amount of serum was de-
termined at 2% FBS to prevent apoptosis and detachment. 
The scratch was made with a 200 pipet tip. The scratch area 
was measured from contrast-phase microscope images taken 
at 20× magnification. Pictures were taken at time zero and 
20 hours (about 50% area was covered). Image analysis was 
performed with the Fiji software28 extracting the area of the 
remaining wound area, and calculating the area covered by 
the cells in 20 hours. Automation of image analysis (n = 30 
or otherwise as indicated) was performed using python 
OpenCV (OpenCV.org) and plotting and statistical analysis 
ANOVA 1-way (Tukey post hoc test) were performed by 
using python-numpy-pandas.
2.8 | Transwell cell migration assay
Directional migration of HeLa cells was measured using 
Fluoroblock Transwells 8  µM (Costar, Cambridge, MA, 
USA) pre-coated with 5  mM FN1for 16  hours, and allow-
ing the cells to migrate in DMEM containing 1% FBS for 
16 hours. Cells on the top and bottom of the fluoroblock tran-
swell membrane were quantified by staining the cells with 
CellTracker Green CMFDA for 30 minutes and fluorescent 
measured using a plate reader Spectramax M5 (Molecular 
Devices, San Jose, CA, USA) at excitation/emission spectra 
(492/517 nm maxima). Each condition represented five in-
dependent experiments. Statistics one-way ANOVA Tukey 
post hoc vs control.
2.9 | Adhesion assay
Cell adhesion assays were adapted from Piccolo et al29 
Briefly, HeLa cells were plated in 100 mm diameter dishes 
at 1 million cells per condition to analyze. Next day, cell 
media were changed to DMEM serum free and left overnight. 
When required, cells were treated with drugs (doxorubicin, 
vorinostat, and GW-4869). Next day, cells were washed with 
serum-free media and collected in PBS containing 10mM 
EDTA for 20 minutes using a cell lifter. Cells were pelleted 
at 600 g for 5 minutes and resuspended in serum-free media 
at 100 000 cells/mL. Enzymatic treatments were applied at 
this step (bSMase, pCDase) for 3 minutes, and media were 
replaced by centrifugation. One milliliter of cell suspen-
sion was added to 35 mm dishes containing 1 mL of DMEM 
containing 1% FBS. Dishes were previously coated with 
fibronectin 5  µg/mL for 16  hours and washed three times 
with PBS. Then cells were left for different amounts of time 
(specified in each case) at 37°C for attachment. Each dish 
was then washed three times with PBS, and cells were fixed 
with 40°C warmed paraformaldehyde at 4% (w/v) in PBS. 
Cells were permeabilized with Triton X-100 0.1% (v/v) in 
PBS and stained for the actin cytoskeleton with rhodhamine-
phalloidin and the nucleus DNA with DAPI. Attached cells 
were visualized using a Leica TCS SP8 laser scanning confo-
cal microscope. Cell number was calculated by the number of 
nuclei, and cell area was determined by the area stained with 
phalloidin-rhodamine. Transfected cells were determined 
using the green channel for Venus-lysenin staining or tagged 
proteins (eg, nSMase2 V5-tagged) using anti-V5 mouse IgG 
labeled with Donkey anti-mouse conjugated to Alexa Fluor 
488. Automatization of imaging processing (cell counting and 
area measurements and statistics) was performed using py-
thon-OpenCV software. Briefly, python-bioformats package 
was used to read raw data from Leica files and extract each 
image channel and metadata. RGB channels were filtered for 
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noise and threshold was set using OTSU method. Individual 
nuclei were detected using the cv2.connectedComponents 
algorithm. Cell area was measured using cv2.contourArea 
algorithm. When transfected cells were used, green chan-
nel was used as a mask on the blue and red channels to only 
count transfected cells. All data plotting was performed using 
matplotlib and Seaborn python packages.
2.10 | Lipid measurements
Lipid measurements were performed as previously described.30
2.11 | Western blot
HeLa cells were plated in 6-well plate (80 000 cells/well). 
Culture media were aspirated and 1% (w/v) SDS was added 
to the cells. BCA protein assay test was used to assess the 
amount of protein, and 20 µg of protein was loaded in SDS-
PAGE gradient gels (4%-20% in Tris-HCl). Proteins were 
transferred onto nitrocellulose membranes and blocked 
in PBS-buffered non-fat milk containing 0.1% Tween-20. 
Primary antibodies were incubated overnight at 4ºC using 
manufacturer-recommended dilutions.
2.12 | Immunofluorescence analysis
HeLa cells were plated in 35  mm diameter uncoated glass 
bottom dishes (MatTek, Ashland MA) at 40 000 cells/dish 
(or 80  000 cells/dish when DNA cell transfection was not 
required) in DMEM-10% FBS and incubated overnight. Cells 
were transfected with plasmid DNA or V5 using Xtremegene 
9 standard protocol. After 16 hours, cell culture media were 
changed to serum-free media for 2 hours before treatments. 
For protein visualization, cells were fixed using fresh, pre-
warmed (40ºC) 4% paraformaldehyde (PFA) for 15  min-
utes. Samples were washed with phosphate-buffered saline 
(PBS) and permeabilized with 0.1% Triton X-100 in PBS for 
20  minutes at room temperature. Permeabilized cells were 
blocked with 2% BSA for 20 minutes and washed with PBS. 
Primary antibodies were added in 2% BSA at recommended 
dilutions (1:500 for V5) and incubated overnight at 4ºC. 
After incubation, samples were washed with PBS, and phal-
loidin and DAPI were added if required for 10  minutes at 
room temperature.
For lipid staining, cold serum-free media were added to 
samples before staining and after treatments. For sphingo-
myelin staining, samples were maintained at 4ºC and freshly 
thawed, cold lysenin in BSA was added to the media, and 
protein-lipid interaction was allowed for 20 minutes. Samples 
were collected on ice and fixed using cold PFA for 30 minutes. 
Then samples were treated as previously described. For cer-
amide staining using the ceramide antibody, samples were 
treated, ceramide antibody was added to serum-free media, 
and samples were kept at 4ºC for 20 minutes. Warmed PFA 
was added to samples and incubated at room temperature for 
15 minutes. For dual protein and lipid staining, samples were 
fixed with warm followed by cold PFA and kept at 4ºC; PFA 
was neutralized with glycine, samples were washed with cold 
PBS, ceramide antibody (1:80 in serum-free DMEM media) 
was added and incubated for 20 minutes, and then fixed as 
described. Images were collected using a Multiphoton mi-
croscope Leica TCS SP8 using a HC PL APO 63X/1.40 oil 
objective CS2.
2.13 | Cell fractionation
Cells were plated in 4 × 15 cm diameter plates at 5 million 
cells/dish and then starved for 24h in serum-free media. Cells 
were then treated with bSMase 10 milli-units for 2 min and 
washed in PBS. Cell fractionation was performed as recom-
mended by Axis-Shield Optiprep density gradient media 
(SIGMA). Cells were collected in lysis buffer [HEPES 
20mM, 2mM KCl, 2mM MgCl2, 0.25M sucrose + protease 
cocktail inhibitors from Sigma cat# P8340] using a cell lifter. 
Cells were disrupted by repeat passages through a needle sy-
ringe [gauge 25G]. Cell lysis was centrifuged at 2000 g for 
10  minutes, and supernatant was centrifuged at 100  000  g 
4°C for 60  minutes. The resultant pellet was resuspended 
in 200microliter lysis buffer and applied into an Iodixanol 
discontinuous gradient [0.5%, 2.5%, 10%, 15%, 20%, and 
30%. Final volume 13 mL] and centrifuged at 28 000  rpm 
(104  000  g average point) in SW28 Beckman rotor for 
20 hours. Following centrifugation, fractions were collected 
from the top to the bottom. Fractions were analyzed for west-
ern blot and for lipid contain using mass spectrometry.
2.14 | Phosphoproteomics analysis
HeLa cells were growth in SILAC media (Fisher PI89985) 
with 10% dialyzed serum (Fisher PI88440) supplemented 
with heavy (13C6 15N4 L-arginine + 13C6 L-lysine) or light 
arginine and lysine. Hela cells (light or heavy labeled) were 
plated in 8 × 15 cm diameter dishes at 5 million cells/dish. 
Media were changed after 4 hours, and cells were incubated 
for 48  hours. Cells were treated with bSMase 10  mU for 
3 minutes, then cells were collected in 4 mL 2.5% (w/v) SDS, 
and cell lysate was frozen at −80C. For each sample, heavy 
and light cell lysates were mixed. Each sample was aliquoted 
in 4 mL. DTT (5 mM, 10 minutes at 55°C) and Iodoacetamide 
(10  mM 30  minutes room temperature, in the dark) were 
added to the samples. About four volumes of methanol at 
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−20°C were added followed by two volumes of −20°C chlo-
roform and three volumes of water. Samples were vortexed 
and precipitated for 1h at −20°C. Samples were centrifuged 
at 4700 g for 20 minutes at 4°C. The upper layer was removed 
without bothering the interphase, 3 volumes of MeOH were 
added and vortexed for 5 seconds, centrifuged at 4700 g for 
20 minutes, and the pellet was frozen until processing. About 
5 mL Urea 8M in HEPES 20 mM was added to each pellet. 
Samples were re-treated with DTT and Iodoacetamide. Urea 
was diluted to 2M with NH4CO3 and samples were digested 
with trypsin overnight. Next day samples were treated with 
TFA final concentration 0.5%. Desalting was performed in 
Waters WAT036810 Sep-Pak Plus tC18, and eluted in 10%, 
20% and 50% TFA and lyophilized. Fractionation of samples 
was performed in Discovery DSC-SCX SPE 1g 52689-U 
eluted from 50-1000  mM KCl. Eluates were dried using a 
SpeedVac and desalted using OASIS 186000367 MAX 3cc 
columns. Phospho-enrichment was performed using TiO2 
resin from GL Science, Japan.
2.15 | Software
Fiji (ImageJ2) was used to measure the scratch area in scratch 
assay and single cell image tracking and quantification of 
fluorescent signal channels. OpenCV was used for image 
analysis for identification of single cells, measurement cell 
area, and measurement of scratch area. Numpy,31 Pandas, 
Matplotlib, and Seaborn were used for data processing, data 
representation, and data clustering. R language32 package 
Graphite,33 and Cytoscape software34 were used for the net-
work generation, analysis, and visualization. NetworkX was 
used to calculate degree of connectivity to filter the network 
for less significant interactions.35 GraphPad Prism (V4.05) 
and Seaborn (V0.9.0) were used for plotting and statisti-
cal analysis. Text mining analysis and gene ontology (GO) 
analysis were performed using Biopython36 and the Uniprot 
Rest API.37 Functional annotation in the network was ex-
tracted from GO database considering only experimental 
evidences. Additional functional annotation was obtained 
via text mining of PubMed abstracts using the gene2pubmed 
relationships files38 and The Comparative Toxicogenomics 
Database.39
3 |  RESULTS
3.1 | Vorinostat, and doxorubicin generate 
ceramide at the plasma membrane
Many previous reports have shown that several chemothera-
peutic treatments modulate the sphingolipid pathway,15,40 
including activation and/or induction of acid and neutral 
SMases (aSMase and nSMase, respectively), especially nS-
Mase 2.41-43 These enzymes localize in certain subcellular 
compartments, such as lysosomes and Golgi, as well as the 
plasma membrane.41,44 In order to focus on the most clini-
cally relevant chemotherapeutic drugs and targeted agents, 
we analyzed the available literature and performed cluster 
studies based on drugs commonly employed in contempo-
rary cancer treatment, for the modulation of sphingolipids 
and their metabolizing enzymes (Figure 1A). From them, 68 
drugs reported to have effects on the sphingolipid pathway 
were categorized based on their P-value using a Fisher t test 
analysis (Table S1). Ten of them, including etoposide, cispl-
atin, vorinostat, paclitaxel, and some anthracyclines (doxoru-
bicin, daunorubicin) presented the most significant P-values 
for ceramide. Doxorubicin was selected as it resulted in 
the most statistically significant increase in the expression 
of nSMase2, which is associated to the plasma membrane, 
and increases in cellular ceramide levels but less significant 
for other bioactive sphingolipids such as S1P and sphingo-
sine. Vorinostat, was also more selective for ceramide and 
nSMase2, and it was also selected in our studies so as to 
provide representatives of two very much studied groups of 
compounds in cancer, albeit with markedly distinct mecha-
nisms of action. Although reported in different cell lines, 
we examined these compounds in HeLa cells for ceramide 
generation. HeLa cells were treated with different sublethal 
doses of doxorubicin (0.6, 0.8, and 1 µM) and vorinostat (2.5, 
5, and 10  µM), and the sphingolipid profile was measured 
at 24  hours after treatment (See Figure S1). As previously 
reported by our group and others, both doxorubicin and vori-
nostat increased ceramide levels, including the most abun-
dant species (C16-ceramide and C24:1 ceramide) by several 
folds (Figure 1B).
However, since the total cellular extract was used for 
the lipid measurements, the increase in ceramide species 
could occur in any subcellular membrane. Currently, there 
is a need for methods to quantify ceramide specifically at 
the plasma membrane. In order to quantitatively analyze 
the ceramide generated at the plasma membrane, we used 
an indirect analytical methodology, based on measuring 
the sphingosine produced by hydrolysis of ceramide at the 
plasma membrane. This method takes advantage that no 
basal or very little ceramide is detected in basal conditions, 
and very low levels of sphingosine are also detected basely. 
When unstimulated cells are treated with pCDase, no cera-
mide (or very little) is hydrolyzed to sphingosine. However, 
if cells are stimulated to generate ceramide in the plasma 
membrane, pCDase generates high levels of sphingosine 
that can only come from ceramide in the plasma mem-
brane. Then the produced sphingosine is in a 1:1 molar 
ratio with the hydrolyzed plasma membrane ceramide. At 
the 24 hours time point after treatment with the different 
drugs, ceramide was acutely hydrolyzed to sphingosine 
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using exogenously added pCDase applied for 5  minutes. 
As shown in Figure 1C, significant levels of sphingosine 
were generated in response of the chemotherapeutic agents, 
thereby demonstrating the production of ceramide that is 
accessible to the exogenous pCDase. Collectively, these 
results establish that doxorubicin and vorinostat generate 
ceramide in the plasma membrane.
Next, we attempted to visualize this pool of ceramide in 
the plasma membrane using a ceramide antibody. To that end, 
we evaluated most of the available anti-ceramide antibodies 
F I G U R E  1  Selected chemotherapeutics induce plasma membrane ceramide. A, Text mining analysis using curated databases on NCBI 
literature (gene2pubmed and CTD database). Common chemotherapy compounds (in x axis) were associated to sphingolipid terms  (in y axis). 
Statistically significant relations between drugs and sphingolipid terms were plotted as adjusted p-values upon exact Fisher test analysis.  
P-values for doxorubicin/ceramide 0.00037, doxorubicin/nSMase2 0.040, vorinostat/ceramide 0.0443, vorinostat/nSMase2 0.0435. B, Total cellular 
ceramide species were measured by mass spectrometry at 24 hours upon chemotherapeutic compounds treatment in HeLa cells. Natural logarithm 
of fold change versus control was plotted in a heatmap and clustered graphs. V-vehicle treatment (methanol). L-low doses (0.6 µM doxorubicin or 
10 µM vorinostat), M-Medium doses (0.8 µM doxorubicin or 15 µM vorinostat), High doses (1 µM doxorubicin or 20 µM vorinostat). C, Detection 
of ceramide at the plasma membrane using recombinant pCDase to form sphingosine. Hydrolysis of plasma membrane ceramide to sphingosine 
is then measured by HPLC-mass spectrometry (see Section 2). Doxorubicin and vorinostat did not induce sphingosine production, but when 
combined with pCDase, the levels of sphingosine dramatically increased, indicating formation of plasma membrane ceramide. D, Validation 
of the anti-ceramide antibody. HeLa cells outer leaflet sphingomyelin and ceramide were stained with fluorescent-lysenin protein, which binds 
sphingomyelin (visualized in magenta), and with anti-ceramide antibody (visualized in green). Control cells (left panel) only showed lysenin but 
not ceramide staining. High doses of bSMase (100 mU and 10 minutes) decreased lysenin staining and markedly increased cell staining with anti-
ceramide antibody (middle panel). Treatment cells with 200 mU pCDase reduced the ceramide staining. E, HeLa cells were treated with different 
chemotherapeutic compounds (doxorubicin 0.8 µM and vorinostat 15 µM) and stained using the anti-ceramide antibody. F, Several images were 
quantified for anti-ceramide antibody showing statistical significance. Statistics one-way ANOVA Tukey posttest *P < .05, ***P < .001
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in HeLa cells3,23,45 even if their specificity to ceramide might 
not have been necessarily established. We ultimately chose 
to use the monoclonal antibody clone 2A2, a mouse IgM 
previously generated and validated against ceramide because 
it empirically stained the cells responding to exogenous re-
combinant sphingomyelinase (bSMase). To validate the an-
tibody and monitor sphingomyelin hydrolysis, this last was 
visualized using the binding probe lysenin conjugated to 
GFP protein as previously reported.7,24 Thus, using bSMase 
(100 mU for 10 minutes), plasma membrane sphingomyelin 
was completely hydrolyzed (Figure 1D, left panel). Ceramide 
was barely detected in untreated cells, but dramatically in-
creased in response to bSMase (Figure 1D, middle panel). To 
assure the ceramide-ligand specificity of the 2A2 monoclonal 
antibody, we employed soluble bacterial ceramidase cloned 
from Pseudomonas (pCDase).7 The co-treatment of cells 
with pCDase and bSMase resulted in loss of binding of the 
ceramide antibody, thus, verifying its specificity (Figure 1D, 
left panel).
Having experimentally confirmed the ligand specificity of 
the monoclonal antibody 2A2 against ceramide, we subse-
quently tested whether the increase in ceramide in response to 
the chemotherapeutical compounds could be detected in the 
plasma membrane. HeLa cells were treated with the ceramide 
inducers, and after 24  hours, a positive signal of anti-2A2 
ceramide monoclonal antibody was detected at the plasma 
membrane, suggesting that at least part of the ceramide gen-
erated was located in the plasma membrane (Figure 1E shows 
representative images). Figure 1F plots the quantification of 
all images (as detailed in Section 2). The anti-ceramide 2A2 
monoclonal antibody in the immunofluorescent experiment 
provided a qualitative measurement of ceramide production 
in the plasma membrane. Based on these results, we conclude 
that treatment with these two chemotherapeutical compounds 
induced ceramide in the plasma membrane.
3.2 | Regulating the generation of plasma 
membrane ceramide at physiological levels
Besides generating ceramide at the plasma membrane, 
doxorubicin and vorinostat are known to trigger many cel-
lular pathways.46 To determine if the formation of plasma 
membrane ceramide had a specific function, we attempted to 
isolate this putative plasma membrane signaling event from 
other compartments by utilizing recombinant bSMase which 
hydrolyzes plasma membrane sphingomyelin, with two ca-
veats: (1) it has been used in large amounts removing most/
all plasma membrane sphingomyelin and possibly acting on 
other phospholipids, and (2) the subsequent re-localization 
of ceramide has not been ascertained. In previous work, we 
showed that bSMase-generated ceramide is not metabolized 
to other known metabolites such as sphingosine, glycolipids, 
or ceramide 1-phosphate within a short (few minutes) time-
frame.7 To establish the localization of this ceramide in the 
early phases after its generation, we measured the sphin-
golipid content in the different cellular membranes by liquid 
chromatography/tandem mass spectrometry (LC/MS/MS) 
upon cell fractionation (Figure 2A) and performed Western 
blotting to assign cellular compartment (CC) distribution 
(Figure 2B). Fractions containing Na-K ATPase but not the 
other cellular markers were considered plasma membrane 
fractions. Heavier membranes (eg, ER-Golgi, mitochondria) 
were evaluated using antibodies specific for calnexin and 
tom 20. The addition of bSMase for 10 minutes caused accu-
mulation of ceramide in the plasma membrane fractions, and 
no detectable changes were found in other membranes. Other 
measured sphingolipids such as sphingosine (Figure  2A), 
along with GlcCer, ceramide-1-phosphate, and sphingosine-
1-phospate did not show any detectable changes. Therefore, 
bSMase not only acts on the plasma membrane generating 
plasma membrane ceramide, but also within the following 
10 minutes, this ceramide is not metabolized to other sphin-
golipids, and it is not mobilized to other cellular membranes, 
but remained, at the plasma membrane. These conditions 
offer a time-window of at least 10 minutes after bSMase that 
can be used as a tool to study ceramide signaling at the plasma 
membrane isolated from more long-term ceramide metabo-
lism or after being translocated to other compartments.
Next, we limited the amount of hydrolysis of SM in 
the plasma membrane in order to mimic more physiologic 
and pharmacologic situations of activation of endogenous 
SMases, which have been shown to hydrolyze up to 20% of 
total sphingomyelin.47 At 10mU bSMase, 10%-20% of sphin-
gomyelin was hydrolyzed, and statistically significant levels 
of ceramide were generated (Figure  2C,D). These results 
demonstrate that physiological increases in ceramide species 
and physiological decreases of sphingomyelin species can be 
mimicked using bSMase and by isolating this signaling event 
from other possible downstream targets and compartments. 
Thus, for subsequent experiments, we utilized 10mU bSMase 
applied for 3 minutes to generate bioactive ceramide at the 
plasma membrane.
3.3 | Phosphoproteomic analysis reveals 
plasma membrane ceramide is involved 
in several biological phenomena with cell 
adhesion proteins constituting a dominant 
functional group
Ceramide-activated protein phosphatases have emerged as 
mediators of many of the cell responses triggered by cera-
mide.1,48 Moreover, protein kinases, especially PKCz, have 
also been advanced as molecular targets for ceramide ac-
tion. Therefore, we evaluated the consequences of ceramide 
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generation in the plasma membrane on the phosphorylation 
status of proteins utilizing phosphoproteomics. HeLa cells 
were cultured in SILAC media (as detailed in Section 2) and 
treated with bSMase (Figure  3A). Around 4000 phospho-
peptides were detected in both control and bSMase-treated 
samples. From this experimental dataset, most phosphopep-
tides did not show changes in their phosphorylation levels 
in response to bSMase, but a significant fraction showed a 
decrease in phosphorylation, and another subset showed an 
increase in their phosphorylation level. For this study, phos-
phopeptides were selected with the following statistical cri-
teria: assuming a normal distribution49 for the changes in 
phosphorylation levels (control/ treated, in log2 scale), ratios 
between Z-score < −1.6 and Z-Score > 1.6 reject the null 
hypothesis with a significance of α = .05 (Figure 3B). This 
selection yielded 114 phosphopeptides that were dephospho-
rylated, corresponding to 88 unique proteins; 117 phospho-
peptides showed increased phosphorylation corresponding 
to 52 unique proteins. Both “dephosphorylated” and “phos-
phorylated” groups had eight proteins in common, meaning 
that these proteins were dephosphorylated at least in one resi-
due, but phosphorylated on at least another distinct residue 
(Figure 3C). Table S2 lists the proteins dephosphorylated and 
phosphorylated in response to ceramide generation.
In order to analyze if some of these ceramide-regulated 
proteins were part of common pathways, we performed an 
enrichment analysis using only curated information from dif-
ferent interactome databases. We combined information from 
STRING (score > 700)50 + Reactome51 + KEGG52 + innat-
eDB53 databases to build a connectivity network. The net-
work was filtered removing nodes with less than 2 degree of 
connectivity54 (Figure 3D). The network was then clustered 
based on biological pathways (Figure 3E). Interestingly, the 
resulting network showed pathways classically related to 
ceramide such as apoptosis,55 cell cycle regulation,56 endo-
cytosis,57 and regulation of MAPK pathways.58,59 However, 
three sets of pathways: “actin cytoskeleton,” “cell migra-
tion,” and “cell adhesion” showed the highest scores in in-
tra-pathway connectivity and inter-pathway connectivity. 
We decided to focus on these biologies, since these were the 
most significant biologies in response to ceramide, they were 
highly inter-connected, and they are biologies  not commonly 
attributed to ceramide.
3.4 | Plasma membrane ceramide regulates 
cell adhesion
Since cell adhesion was the main functional class found for 
the largest number of identified phosphoproteins, we aimed 
to explore whether this prediction translates into specific cel-
lular activities. Thus, HeLa cells treated with bSMase were 
F I G U R E  2  Generation of ceramide at the plasma membrane in physiological conditions. A, Percentage in ceramide and sphingosine content 
measured upon bSMase treatment 100 mU for 10 minutes. After treatment, cellular membranes were separated using gradient centrifugation 
optimized to separate plasma membrane from heavier membranes. Frc1-20 refers to the first 20 fractions collected. Sphingosine (Sph); ceramide 
with C16-acyl chain (C16Cer); ceramide with C24:1 acyl chain (C24:1Cer). B, The identification of the different cellular membranes was carried 
out using established marker proteins by Western Blot. For plasma membrane, the Na/K ATPase was used. For heavier membranes, calnexin and 
Tom20 were used as markers for endoplasmic reticulum and mitochondria, respectively. C, Mass spectrometry analysis of sphingomyelin content 
per 500 µg cellular protein after treatment with increasing amounts of bSMase (in milliunits). D, Same samples were also processed for ceramide 
quantification by mass spectrometry analysis. Statistics one-way ANOVA Tukey posttest vs control. *P < .05, **P < .01, ***P < .001
10 |   CANALS et AL.
F I G U R E  3  Interrogating ceramide function at the plasma membrane. A, Scheme of the phosphoproteomics experiment. HeLa cells were 
cultured in SILAC media containing (isotopically) heavy or light amino acids as described in Materials and Methods for at least 7 doubling to 
ensure incorporation in all cellular proteins. Cells fed in light conditions constituted the untreated (control) group, while cells fed with heavy 
amino acids were treated with bSMase 10 mU for 2 minutes (LH experiment). A replicate experiment was also performed treating cells fed in light 
conditions with bSMase, while cells fed with heavy amino acids were untreated (HL experiment). Cells were collected in lysis solution as indicated 
in Materials and Methods, and light and heavy protein lysates were mixed, proteins were digested, phospho-enriched and phosphopeptides 
were quantified by mass spectrometry analysis. B, The distribution of both experiments on the natural logarithm of the ratio (treated/ control) 
of the detected abundance of each phosphopeptide detected followed a normal distribution. C, Statistically significant ratios were assigned to 
phosphorylation or dephosphorylation events in response of treatment (P-value .05). The Venn diagram shows the number  of proteins for each 
group. Note that eight proteins contained both events but on different phospho-sites. D, Network analysis for proteins dephosphorylated (light 
green) and phosphorylated (dark green) enriched with interactions in Reactome+ String + KEGG + innateDB. To reduce less significant edges, 
the network was filtered for 3 or more degree of connectivity using NetworkX software. E, Pathway analysis of the build network was performed 
using Reactome database, and more statistically significant pathways (Fisher test) were selected. Pathways cluster node size are proportional to the 
intra-connectivity value and edges represent connections between proteins from within pathway clusters. Pathway clusters under a general GO term 
within the same hierarchy biology are colored with the same color (eg, cell adhesion pathways are colored in magenta). Color codes are indicated in 
legend figure
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tested for cell adhesion as detailed in Section 2. Treatment 
with bSMase dramatically reduced the ability of cells to at-
tach on fibronectin (Figure  4A), suggesting a critical role 
played by ceramide in this setting.
As an immediate consequence of cell adhesion, we also 
measured cell spreading which requires the deformation of 
the plasma membrane and the formation of cell-substrate at-
tachments. The area of the attached cells was measured and 
monitored for each attached cell during the 2-hour period 
of the assay (Figure 4B,C). The results showed that plasma 
membrane sphingolipids not only regulate the initial cell ad-
hesion, but also affected cell spreading.
Given the established reciprocal changes in sphingomy-
elin and ceramide, we reasoned that it would be important to 
determine whether the effects of bSMase were due to the gain 
of ceramide or to the loss of sphingomyelin. To differentiate 
between these possibilities, HeLa cells were co-treated with 
an excess of recombinant soluble pCDase to hydrolyze cera-
mide formed by the action of bSMase. Figure 4D,E show that 
exogenously added pCDase had no effect on cell adhesion 
per se. However, pCDase significantly countered the effect 
of SMase. These results suggest that the generation of cera-
mide, and not the loss of sphingomyelin, was the main me-
diator of effects on cell adhesion to the extracellular matrix. 
F I G U R E  4  Plasma membrane ceramide regulates cell adhesion. A, HeLa cells were scraped from culture dish in 10mM EDTA, washed in 
PBS by centrifugation and resuspended in serum-free DMEM media. Cell suspension was treated with bSMase 10 mU or vehicle for 2 minutes and 
washed in PBS and resuspended in low FBS media (1%). Cells were then re-plated in fibronectin1-coated dishes as specified in methods section. 
At different time points after re-plating, the dishes were washed from floating cells and the cells fixed with paraformaldehyde. Attached cells were 
stained with phalloidin-rhodamine and DAPI and visualized using fluorescent microscopy (representative images in B). Images from independent 
experiments (n = 15) were used for cell counting and (C) cell area quantification. Area quantification represents n > 1000 cells and was performed 
by image processing software as described in methods. D, Adhesion assay was performed treating cells in suspension prior to re-attachment with 
bSMase, pCDase or [bSMase + pCDase] together. Representative images shown, and (E) quantification. Statistics one-way ANOVA Tukey 
posttest vs control (*) or vs pCDase-combined treatment (#). * or # P < .05, ** or ## P < .01, *** or ### P < .001
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Also, considering that pCDase acts only on ceramides, the 
results further support that the phenotype is mediated by 
the ceramide product specifically and not any subsequent 
metabolite(s).
3.5 | Plasma membrane ceramide enhances 
cell migration
Functionally, cell adhesion has been implicated in both in-
creased cell migration with loss of adhesion allowing cells to 
migrate and in impairment of cell migration through loss of 
the required mechanical support on the extracellular matrix 
during movement. Moreover, cell migration can be evaluated 
using different assays that assess the different types of cell 
migration. The wound healing assay was first chosen due to 
its technical simplicity, which enables simultaneous multi-
plex testing of many different experimental conditions and 
because it evaluates collective cell migration.60 HeLa cells 
were seeded on fibronectin at confluent density. A scratch 
was made, and migration of cells was serially monitored at 
different times. After 20h, 40%-60% of the scratch was cov-
ered, and this time point was chosen to evaluate the effects of 
plasma membrane ceramide manipulation. bSMase (10 mU/
mL) treatment dramatically increased cell migration, with 
cells practically covering the entire area by 20  hours (rep-
resentative images are shown in Figure 5A). Quantification 
of independent experiments is plotted in Figure 5B (n = 15, 
P < .001). These results show that the generation of ceramide 
at the plasma membrane reduced adhesion and accelerated 
migration of cells.
Next, single cell migration was measured in transwell 
assays on fibronectin 1-coated membranes. HeLa cells re-
sponded to increasing amounts of bSMase with increas-
ing cell migration in a concentration-dependent manner 
(Figure 5C, and representative images of migrated cells on 
Figure 5D).
Finally, we aimed to visualize the increase in cell mi-
gration using live imaging microscopy. The positions of 
individual cells were tracked for 16 hours. Cells stimulated 
with bSMase underwent a marked increase in cell migration 
(Figure  5E, quantified in 5F, and Video S1). These results 
demonstrate that hydrolysis of SM to produce ceramide at the 
plasma membrane is sufficient to trigger an increase in cell 
migration phenotype.
Moreover, cells co-treated with pCDase overcame the ef-
fects of bSMase on migration (Figure 5G), confirming that 
the effects on cell migration were mediated by the production 
of ceramide and not by loss of sphingomyelin or by further 
metabolism of ceramide (to sphingosine and then to S1P).
Collectively, these results strongly suggested that plasma 
membrane ceramide modulates cell adhesion, spreading, and 
migration.
3.6 | Activation of endogenous 
programs for the generation of plasma 
membrane ceramide
Next, it became important to determine whether endogenous 
enzymes associated with ceramide generation were able to in-
duce ceramide at the plasma membrane and to regulate cell 
adhesion. We focused on nSMase2 because it has been re-
ported to respond to doxorubicin and vorinostat increasing the 
mRNA and protein levels, and it has also been reported to be 
located at the plasma membrane.26,61,62 However, its ability 
to generate ceramide at the plasma membrane has not been 
documented. To test if expression of this enzyme26 would 
be sufficient to generate ceramide at the plasma membrane 
and trigger the same biological phenotypes as seen with the 
bSMase treatment, we first expressed and confirmed by im-
munostaining that nSMase2 was localized at the plasma mem-
brane in HeLa cells (Figure 6A upper panels). As shown with 
the 2A2 anti-ceramide monoclonal antibody, recombinant 
nSMase2 was capable of generating qualitative amounts of 
ceramide (lower panels) in the plasma membrane; however, 
the effects on changes in the plasma membrane sphingomy-
elin were only modest (Figure 6A middle panels). The pres-
ence of ceramide in the plasma membrane was also confirmed 
using recombinant pCDase as previously shown. HeLa cells 
transfected with nSMase2 were treated with pCDase, and the 
sphingosine generated was measured. Control cells did not 
show a statistically significant increase in sphingosine lev-
els whereas cells expressing nSMase2 showed an increase in 
sphingosine, concluding that overexpressing nSMase2 is suf-
ficient to increase plasma membrane ceramide (Figure 6B).
Cell adhesion and spreading were next evaluated under 
these experimental conditions. Similar to the bSMase treat-
ment, expression of nSMase2 impaired both functional ac-
tivities when compared to non-transfected control cells. As 
observed for bSMase, the addition of pCDase during the cell 
adhesion assay was sufficient to revert the effects on loss of 
adhesion and cell spreading (Figure 6C,D, representative im-
ages in Figure 6E). These results indicated that the effects on 
cell adhesion and cell spreading by nSMase2 were mediated 
by plasma membrane ceramide.
Since the effects of ceramide on cell adhesion also inter-
fered in migration when bSMase was used, it was predicted 
that overexpressing of nSMAse2 also should modulate cell 
migration. HeLa cells were transfected with nSMase2 and 
evaluated for changes in cell migration using the wound 
healing assay. Cells expressing nSMase2 showed accelerated 
rates in closing the wound, suggesting an effect on cell migra-
tion (examples of representative experiments in Figure  6F, 
quantified in Figure 6G). The effect on cell migration were 
extended by tracking cell motility on individual cells follow-
ing cell motility on FN1 under the microscope taking pic-
tures every 10 minutes for 20 hours, confirming the effect of 
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nSMase2 on cell motility (examples of individual tracks in 
Figure 6H, quantified in Figure 6I).
From these experiments, we concluded that increased ex-
pression of nSMase2 generates ceramide at the plasma mem-
brane and this level of ceramide was sufficient to induce loss 
of cell adhesion, loss of cell spreading increasing cell migra-
tion rate.
3.7 | Doxorubicin and vorinostat induced 
loss of cell adhesion and increased cell 
migration mediated by nSMase2 and ceramide 
at the plasma membrane
As previously reported,15 both doxorubicin and vorinostat 
induce cellular ceramide, and in Figure  1 we showed this 
F I G U R E  5  Generation of plasma membrane ceramide increases cell migration. A, Scratch wound healing migration assay in HeLa cells 
treated with bSMase was performed for 20 hours. Random images at time zero and after 20 hours are shown. Yellow color highlights the wound 
area. B, quantification of independent experiments (n = 10) showed that bSMase induced cell migration. Statistics t test ***P < .001. C, Cell 
migration in transwell using Fluoroblock. Different amounts of bSMase were added into the upper well for 2 min, washed and cells were left to 
migrate for 16 hours. Cells were stained with cell tracker, and fluorescence was read from the bottom using a plate reader. Statistics one-way 
ANOVA Tukey post hoc vs bSMase 0 mU. D, Random images of migrated cells stained with Red cell tracker, and visualized in a fluorescent 
microscopy. E, Live imaging of cell migration was performed in confocal dishes coated with fibronectin-1. Cells were plated at low confluency and 
low-serum media, bSMase was added to plates for 2 minutes, and images were taken every 15 minutes for 16 hours. Individual cell position was 
tracked using imaging processing software as detailed in Methods. Individual cells tracks were plotted for qualitative view, and (F) total distance 
for each individual cell was measured as the sum of the travelled distance each 15 minutes up to 16 hours. Student t test ***P < .001. G, Scratch 
assay on cells treated with bSMase, pCDase, and with the combination of both [bSMase + pCDase]. One-Way ANOVA Tukey post hoc test 
*P < .01. #One-way ANOVA Tukey post hoc vs bSMase
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ceramide is at least partly located in the plasma membrane. 
We reasoned that generation of ceramide at the plasma mem-
brane level may be sufficient to induce cell detachment and 
cell migration. Taking this experimental evidence into ac-
count, we predicted that vorinostat and doxorubicin may also 
induce loss of cell adhesion and stimulate migration. To our 
knowledge, there are no previous reports on doxorubicin or 
vorinostat modulating cellular adhesion. However, there are 
a few reports where a connection was found between cell ad-
hesion molecules and doxorubicin. For instance, FAK pro-
tein was found to antagonize doxorubicin cardiotoxicity63 
and doxorubicin when combined with other drugs reduced 
F I G U R E  6  Expression of nSMase2 is active at the plasma membrane and recapitulates bSMase effects on cell adhesion. A, V5-tagged 
nSMase2 expressing HeLa cells and visualized (upper panels:V5 staining in green, phalloidin-rhodamine [F-actin cytoskeleton] in red, and DAPI 
[nucleus] in blue). The effects of the enzymes in the plasma membrane were also visualized by staining outer leaflet sphingomyelin (Middle panels 
using venus-lysenin, green) and ceramide (bottom panels, ceramide antibody in red). B, Control cells and cells expressing recombinant nSMase2 
for 24 hours were treated in serum-free media with PBS (blue bars) or 200 mU of pCDase (brown bars) for 5 minutes. Cells were collected in 
organic solvent and analyzed for sphingosine content by HPLC-MS. Samples were normalized based on inorganic phosphate (Pi) content. C, Cells 
expressing the neutral nSMase2 were evaluated for cell adhesion. Cells were scraped from dish in EDTA and re-plated in fibronectin1-coated 
dishes. After 60 minutes, floating cells were washed, and attached cells were fixed with paraformaldehyde. Cells were stained for nuclei (DAPI) 
and F-actin cytoskeleton (rhodamine-phalloidin) and visualized in a fluorescent microscopy. Cells were counted in 10 independent experiments 
and (D) cell area was measured in >1000 cells using image processing software as detailed in methods. E, Random images are shown. F, Scratch 
wound healing migration assay in HeLa cells overexpressing nSMase2 was performed for 20h. Random images at time zero and after 20h are 
shown. Yellow color highlights the wound area. G, Fifteen independent experiments were quantified. Statistics t test ***P < .001. Random images 
are displayed. H, Control cells and cells expressing nSMase2 for 24 were seeded on fibronectin FN1. Cell migration was recorded for 16 hours, and 
individual cell tracks were graphed on a dispersion plot. I, Total distance for each individual track in (H) was calculated and total distance for 25 
individual cells were plotted. Statistical test were t test (*P < .05, **P < .01, ***P < .0001) for G and I, one-way ANOVA with Tukey post hoc 
test for C and D. Two-way ANOVA for B. For C and D, * vs control, # vs nSMase
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adhesion of breast cancer cells.64 Moreover, these two com-
pounds were selected in this study because they have been 
shown to induce transcription of nSMase2. We hypothesized 
that induction of nSMase2 by these compounds will generate 
ceramide in the plasma membrane that would trigger loss of 
cell adhesion and induce cell migration. In order to test this 
hypothesis, first we validated that the two compounds were 
also capable to induce nSMase2 in HeLa cells. As reported 
for other cell lines, both compounds at sublethal concentra-
tions were capable to induce nSMase2 mRNA in a dose-de-
pendent manner in HeLa cells (Figure 7A). Next, we tested 
if the generation of plasma membrane ceramide induced by 
doxorubicin and vorinostat was dependent on nSMase2, and 
its generation could be blocked by inhibition of nSMase2. As 
shown in Figure 1, we measured indirectly ceramide using 
pCDase and measuring the generation of sphingosine, and 
as shown in Figure 1, both compounds generated ceramide 
at the plasma membrane. Inhibition of nSMase2 was ac-
complished using the pharmacological inhibitor GW-4869. 
Inhibition of nSMase2 blocked the increase of plasma mem-
brane ceramide in response to doxorubicin and vorinostat 
(Figure 7B). GW-4869 had no statistically significant effect 
in control conditions, but the mean of ceramide measured 
was decreased. In order to test if GW-4869 per se could affect 
the levels of ceramide independently of nSMase2 activation, 
GW-4869 was tested on plasma membrane ceramide gener-
ated using bSMase. In this scenario, GW-4869 failed to block 
bSMase and ceramide generation at the plasma membrane. 
This last result confirmed that the effects of GW-4869 were 
due to blockage of ceramide generation, and not secondary 
effects on plasma membrane sphingolipids (Figure 7C).
The previous experiments allowed us to modulate the 
levels of plasma membrane ceramide generated in response 
to the chemotherapeutical compounds and use these tools to 
study if this specific pool of ceramide had the same biology 
that the one mimicked using bSMase. HeLa cells were treated 
with sublethal doses of vorinostat and doxorubicin, and the 
two compounds resulted in loss of cell adhesion. Inhibition of 
nSMase2 activity was evaluated using the inhibitor GW-4869, 
and it blocked the loss of cell adhesion induced by the two 
compounds (Figure 7D). Knock down of nSMase2 achieved 
the same results proving that the effects of GW-4869 were 
due to targeting nSMase2. The use of recombinant pCDase 
confirmed the role of plasma membrane ceramide on doxo-
rubicin and vorinostat effects on cell adhesion (Figure 7D). 
Therefore, the loss of cell adhesion induced by the chemo-
therapeutical compounds was regulated by ceramide gener-
ated by induction of nSMase2, and this ceramide was acting 
at the plasma membrane level.
From the previous results, the generation of ceramide 
from doxorubicin and vorinostat is also expected to modulate 
cell migration. Again, we used the wound healing assay to 
screen for several conditions and summarized as % cell mi-
gration versus untreated control cells (Figure 7E). First, we 
confirmed that both chemotherapeutical compounds induce 
cell migration in HeLa cells. Then we used both siRNA for 
F I G U R E  6 .  Continued
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nSMase2 and GW-4869 inhibitor to block nSMase2 effects 
on ceramide, and both methods completely abolished the in-
crease in cell migration returning to basal levels, confirming 
the role of nSMase2 on allowing the induction of cell mi-
gration. To consolidate the role of the ceramide formation 
we used pCDase during the cell migration assay. Increasing 
concentration of pCDase resulted in more inhibition on cell 
migration. This last result also confirmed that ceramide pro-
duced by nSMase2 upon chemotherapy induction was  nec-
essary to trigger cell migration and it was still located at the 
plasma membrane.
Interestingly, some chemotherapeutical compounds, 
including doxorubicin and vorinostat, have been reported 
to induce cell migration in some cell lines, contributing 
to the risk of cancer invasion to surrounding tissues and 
generating metastatic lesions. Since our data showed that 
loss of cell adhesion (which is shown to be related to a po-
tential increase in cell invasion) and gain in cell migration 
were dependent on plasma membrane ceramide, we tested 
GW-4869 to block random cell migration on individually 
tracked cells upon stimulation. We chose vorinostat for this 
assay (unfortunately, doxorubicin-treated cells underwent 
F I G U R E  7  Chemotherapeutics induce loss of cell adhesion and induction of cell migration, mediated through plasma membrane nSMase2/
ceramide axis. A, Doxorubicin and vorinostat at the indicated concentrations were evaluated for expression of nSMase2 measured by RT PCR. 
Messenger RNA was quantitated at 24 hours after induction. Validation of siRNA sequences on control (nSMAse KD) and induced samples (doxo 
+ KD and Vor + KD) by RT-PCR. B, Control cells and cells treated with doxorubicin 0.8 µM, vorinostat 10 µM, or co-treated with GW, were 
treated in serum-free media with PBS (blue bars) or 200 mU of pCDase (brown bars) for 5 minutes. Cells were collected in organic solvent and 
analyzed for sphingosine content by HPLC-MS. Samples were normalized based on inorganic phosphate (Pi) content. Statistics were two-way 
ANOVA with post hoc analysis. N.s—no significant. *P < .05, **P < .01, ***P < .001, ****P < .0001. C, Cells in serum-free media were treated 
with PBS (control) or bSMase (bSM) 10 mU for 3 minutes. Media was replaced for fresh serum-free media and treated with pCDase (+pCD) for 
20 minutes. Sphingosine was quantified as described in panel (B). Samples GW were pre-treated for 20 hours with GW inhibitor. D, Heatmap 
summarizing the results on cell adhesion assays, orange color indicating gain of adhesion and blue loss in cell adhesion compared to untreated 
control cells (given value of 100% attachment). Chemotherapeutical compounds doxorubicin (Doxor) and vorinostat (Vorino) resulted in loss of 
cell adhesion. Inhibition of nSMase2 with siRNA or GW (nSMase inhibitor) blocked the effects of doxorubicin and vorinostat on cell adhesion. 
Cells treated with increasing doses of pCDase (25, 50 and 200 mU) before re-attachment overcame the effects on loss of cell adhesion in a dose-
dependent manner. Two independent experiments are shown per each condition). E, Heatmap summarizing scratch assays on cells treated with the 
two chemotherapeutical compounds. Orange color represents increase in cell migration (as % vs control untreated cells) and blue color a loss on 
cell migration vs control cells. Each condition is shown as two independent experiments. The two compounds, doxorubicin (Doxor) and vorinostat 
(Vorino). F, Individual cell migration assay on cells treated with the inhibitors GW upon chemotherapeutical compound vorinostat
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cell death when they were exposed to the laser light in the 
microscope, rendering it technically unreliable to track 
them). Cells exposed to sublethal doses of vorinostat were 
stimulated for random migration. GW-4869, which had 
no effect on basal migration, blocked vorinostat- induced 
migration (Figure 7F). This assay not only confirmed the 
results on the wound healing assay using an independent 
approach, but it also demonstrates that a small molecule in-
hibitor of nSMase2 can be used to block individual cell mi-
gration potentially induced after chemotherapy treatment.
Together, these results showed that some chemothera-
peutical compounds, at sublethal doses, induce a loss in 
cell adhesion followed by an increase in both collective 
and individual cell migration. This gain of function can 
be blocked by specifically targeting plasma membrane 
ceramide, which can be achieved by inhibiting nSMase2 
activity.
4 |  DISCUSSION
In this study, we provide evidence of a specific pathway 
launched by nSMase2 acting on plasma membrane sphin-
gomyelin to generate ceramide in the same compartment. 
This ceramide acutely triggers changes in the phosphoryla-
tion status of a set of proteins, which were predicted in-sil-
ico to be part of a network regulating cell adhesion and cell 
migration. Experimental results confirmed this prediction 
and defined these biologies as a cell anti-adhesion program 
resulting in enhancement of cell migration. Furthermore, 
this mechanism was found to fit the biological niche down-
stream of chemotherapeutical compounds inducing cell 
migration. Finally, enzymatic or pharmacological modula-
tion of the cellular surface ceramide prevented the effects 
of these chemotherapeutics on enhancing cell migration, 
suggesting new avenues in optimizing cancer cell therapy.
A major conclusion from this study is in defining a 
mechanism-based specific action of sublethal chemother-
apeutic agents on cell adhesion and migration. It has been 
suggested for many years that many chemotherapeutical 
treatments can affect cancer cells in a paradoxical way that 
might increase tumor cell spreading and metastatic dissem-
ination.65,66 Taxanes,65,67 anthracyclines such as doxorubi-
cin,65 and platinum salts such as cisplatin67 are some of 
the drugs implicated in potentially increasing metastatic 
tumor cell spreading of cancers. Reported molecular mech-
anisms to explain these effects involve overexpression and 
or activation of adhesion proteins, such as FAK,68 ROCK,69 
RhoA/MLC,22 ezrin,69,70 src,70 and EpCAM.71 However, 
the mechanism on how these proteins are regulated by 
chemotherapy or whether each reported adhesion protein 
works individually toward regulation of cell adhesion, 
or they actually work as part of a network has not being 
explored. The results in this work reveal that a pool of ce-
ramide in the plasma membrane mediates the effects of at 
least two chemotherapeutical compounds on enhancing 
cell migration and loss of cell adhesion. This hypothesis is 
supported by several lines of evidence. First, Doxorubicin 
and vorinostat induced expression of nSMase2 which was 
necessary to trigger loss of cell adhesion and cell migra-
tion. Second, overexpression of recombinant nSMase2 
was sufficient to trigger the same biology. Third, the use 
of bSMase to artificially generate ceramide at the plasma 
membrane, at physiologically and pharmacologically rele-
vant levels, recapitulated nSMase2 effects on cell adhesion 
and migration. Moreover, plasma membrane ceramide gen-
erated using bSMase was sufficient to regulate a network 
of cell adhesion proteins within just 2-3 minutes after its 
generation. Fourth, removal of this pool of ceramide using 
recombinant enzymes blocked the effects on adhesion and 
migration, independently from the source of this plasma 
membrane ceramide (bSMase, nSMase2, doxorubicin and 
vorinostat), and finally, pharmaceutical or genetic inactiva-
tion of nSMase blocked the effects on adhesion and migra-
tion upon doxorubicin and vorinostat treatment, but failed 
to block the effects upon bSMase treatment. Altogether, 
although we cannot rule out that other sphingolipids can 
originate from metabolism of this identified pool of cera-
mide and might be also involved in the studied biologies, 
these results strongly suggest that the mechanism by which 
chemotherapy induces cell migration requires ceramide at 
the plasma membrane, generated by increase expression of 
nSMase2.
These results are potentially very significant for cancer 
treatment. As mentioned above, sublethal doses of chemo-
therapy might increase the chances of cancer cell invasion 
and eventually cancer metastasis. Here, at sublethal concen-
trations of two chemotherapeutics, we still measure signif-
icant ceramide production, and we find it is necessary and 
sufficient to mediate the effects on cell adhesion and migra-
tion. Based on the present study, it could be speculated that 
reducing ceramide levels at the plasma membrane could be 
used combined with chemotherapy to reduce the potentially 
undesired effects on cell spreading. We showed that phar-
macological inhibition of nSMase2 using GW significantly 
reduced the production of plasma membrane ceramide and 
completely blocks the effects of chemotherapy on cell mi-
gration and cell adhesion, and potentially reduce the risk of 
cancer spreading.
Another major conclusion from this study is that cera-
mide can act at independent subcellular compartments to 
couple to specific biologies. One of the conclusions of the 
“Many ceramides” hypothesis  is  that the different pools 
of ceramide might coexist in the cells, possibly regulating 
different biological processes.9 Changes in ceramide levels 
upon cell treatment or cell stress are routinely measured at 
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the whole cell levels,30 thus, mixing all subcellular compo-
nents and treating ceramide as one unique entity. This might 
represent a problem by ignoring or masking changes in 
some compartments compared to other compartments that 
may contribute more to the total mass of cellular ceramide, 
but with potentially dramatic effects on the cell fate. In that 
way, only changes in ceramide that are comparable to the 
whole cellular ceramide pool would be detected with the 
possibility to be related to certain biologies, for example as 
it has been done for cell death.55 There are just a few exam-
ples where a specific pool of ceramide have been suggested 
to be generated with functionality in one particular compart-
ment.5,72 However, this idea has not been further developed, 
probably because of the lack of tools that allow us to detect 
ceramide in specific compartments, and to be able to modu-
late ceramide levels in that specific compartment. Ceramide 
antibodies have been successfully used to detect ceramide 
production in individual cells and in tissues.45,73 However, 
they have not been used to dissect the ceramide topology, 
and based on individual images, it is a qualitative more than 
a quantitative tool. We have developed a new assay to mea-
sure ceramide at the plasma membrane based on quantify-
ing sphingosine as the result of the hydrolysis of the plasma 
membrane ceramide by adding exogenous recombinant and 
purified CDase and measuring the generated sphingosine 
by mass spectrometry. This method has allowed us to detect 
changes in ceramide levels in the plasma membrane, that 
otherwise would have been diluted by the whole cell cer-
amide. With respect to chemotherapeutics, we know from 
previous studies and this one that ceramide production upon 
chemotherapy is capable to mediate different biologies. For 
example, at lethal concentrations, doxorubicin, and vorinos-
tat are reported to increase ceramide, and this ceramide is 
necessary to induce cell death.74-76 This would be consis-
tent with the ability of mitochondrial ceramide to induce 
cell death.5,77 Moreover, the current results not only demon-
strate that plasma membrane ceramide has functions differ-
ent from those classically assigned to cellular ceramide, but 
also new functions not previously directly attributed to ce-
ramide. Thus, compartment-specific functions of ceramide 
are becoming indispensable for our understanding of the 
functions of various ceramides. Moreover, we can hypoth-
esize that analogous tools working in different subcellular 
compartments would unveil new functions of ceramide, or 
at least assign known ceramide functions to specific pools 
of ceramide.
This work supports the idea of ceramide as a second 
messenger, where low or non-present ceramide levels in the 
plasma membrane increase in response of signaling events 
resulting in changes in the phosphorylation status of several 
proteins, many of them responsible to regulate biologically 
significant changes in cell adhesion and migration. Although 
we have identified the first ceramide responders toward 
regulation of these biologies, we have not identified the di-
rect targets and mediators of ceramide. However, we suspect 
that since protein kinases and protein phosphatases have been 
reported to be directly modulated by ceramide in vitro, and 
the effects we found are in changes in phosphorylation levels, 
we suspect a direct or very first responder of ceramide would 
be a protein kinase or a protein phosphatase. Our group is 
currently working toward this direction.
In this work we have also advanced the understanding 
on nSMase2. The localization and place of actions of nS-
Mase2 are still unclear;  all works on localization are based 
on tagged recombinant forms, and not based the endoge-
nous enzyme.26,41 Recombinant forms of nSMase2 localize 
in the ER-Golgi and in the plasma membrane. Less is known 
about its substrate subcellular localization. Here, we show 
that both physiologically induced and recombinant overex-
pression of nSMase2 are capable to form ceramide at the 
plasma membrane. This function in the plasma membrane 
was highly suspected, but not confirmed. In this work we 
were able to visualize with the ceramide antibody ceramide 
generation at the plasma membrane upon induction of en-
dogenous nSMase2 or overexpression of nSMase2. Using 
recombinant pCDase coupled with detection of sphin-
gosine, we were also able to measure this ceramide gener-
ated at the plasma membrane. These results do not rule out 
that ceramide might be formed in other membranes in re-
sponse to nSMase2, but they do demonstrate that ceramide 
can function at least at the plasma membrane. Exposing 
cells to bSMase or overexpressing nSMase2 resulted in 
the same phenotype on cell adhesion, cell spreading and 
cell migration, dependent on plasma membrane ceramide. 
Bacterial sphingomyelinase acts on the outer leaflet of the 
plasma membrane, whereas nSMase2 is believed to act on 
the inner leaflet of the plasma membrane.61,62 However, 
ceramide generated from nSMase2 can be detected in the 
outer leaflet as evidenced with the ceramide antibody and 
the use of recombinant pCDase, suggesting that ceramide 
can quickly equilibrate between two membrane bilayers as 
also shown by others.78
The current results show that nSMase2 not only acts at 
the plasma membrane, but also it is an essential compo-
nent of a program regulating cell adhesion, spreading, and 
migration. NSMase2 is involved in the cell cycle, and it 
has also been found to mediate TNF and CD95 responses 
toward cell death.1 nSMase2 has been only indirectly 
shown to be related to cell adhesion, such as modulating 
some proteins with roles in cell adhesion such as ICAM,79 
and integrins,80 in the regulation of chemokines,81,82 and 
even more indirectly affecting somehow cytoskeletal pro-
teins.40 Here, we have shown that nSMase2 is required for 
the physiological regulation of cell adhesion and cell mi-
gration. Knockdown of nSMase2 was sufficient to revert 
the chemotherapeutic drug effects on cell migration and 
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adhesion, whereas overexpression of nSMase2 was suf-
ficient to trigger these functions. Also, it is important to 
mention that probably other sphingolipid metabolizing en-
zymes capable to acutely modulate ceramide levels at the 
plasma membrane are part of this pathway. Thus, sphingo-
myelin synthase 2 and neutral ceramidase are two immedi-
ate candidates to play roles in cell adhesion and migration 
and should also be evaluated.
In summary, we have defined plasma membrane ceramide 
as an independent and as yet unappreciated second messen-
ger that is triggered by some cytotoxic drugs, mediating loss 
of cell adhesion and spreading while enhancing migration. 
We have defined a previously unrecognized plasma mem-
brane ceramide cell signaling pathway. Finally, one might 
speculate on inhibition of nSMase2 as a viable strategy to 
prevent or mitigate potentially undesirable effects of cancer 
chemotherapy.
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